Bridge Biotherapeutics Enters into an Exclusive License Agreement with Shaperon to Strengthen Its IPF Franchise
* The licensing deal includes an upfront payment of USD 1.63 million, and may reach up toUSD 24.4 million in milestone payments and royalties * By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive tre...
Bridge Biotherapeutics Presented the Preclinical Data of BBT-207 at the AACR Annual Meeting 2022
* The preclinical data supports the clinical development of BBT-207 for EGFR mutant NSCLC patients harboring C797S double mutations, as well as for those who are treatment-naïve * The company plans to submit an IND application to the US FDA in 2022 and looks forward to entering the Phase 1 st...
Bridge Biotherapeutics to Present Preclinical Data of BBT-207 at the AACR 2022 Annual Meeting
* The abstract of BBT-207 pre-clinical studies is now available at the AACR website * Preclinical data suggests that BBT-207 may have the potential to be positioned as a frontline treatment with the anti-tumor effects in EGFR mutant NSCLC SEONGNAM, South Korea, March 9, 2022 /PRNewswire/ -- B...
Bridge Biotherapeutics Enters into an Option-to-License Agreement with CellionBioMed to Develop BBT-301 for the Treatment of Multiple Fibrotic Diseases
* The company reinforces its strategic focus on fibrotic diseases including idiopathic pulmonary fibrosis (IPF) * Through the option-to-license agreement, Bridge will develop a novel anti-fibrotic ion channel modulator, which is a preclinical candidate SEONGNAM, South Korea, March 7, 2022 /PR...
Bridge Biotherapeutics and Scripps Research Launch Research Collaboration to Develop Discovery Platform and Novel Covalent Probes Based on Chemical Biology and Chemoproteomics
* Two-year research collaboration to develop new reactive group chemistries targeting non-cysteine amino acids to expand druggable binding sites and identify novel targets in oncology and immunology * Collaborators at Scripps are pioneers in the field of chemical biology and chemistry SEONGNA...
Bridge Biotherapeutics Announces Initiation of the Phase I Clinical Trial for BBT-401 in China
* China Phase I study of BBT-401 had its first subject dosed in Chengdu, China * The company seeks to accelerate its business development activities with Daewoong, their partner for the development and commercialization of BBT-401 in 22 Asian countries SEONGNAM, South Korea and CHENGDU, China, ...
Bridge Biotherapeutics Presents Pre-Clinical Data of BBT-176 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
* Pre-clinical data exploring the in vitro and in vivo efficacy of BBT-176 will be disclosed via an ePoster at the ESMO Congress 2021 * Patient dosing for the phase 1/2 clinical study of BBT-176 was initiated in April 2021…the topline data of the first-in-human, dose escalation study is expec...
Bridge Biotherapeutics Announces the Initiation of Patient Dosing in the Proof of Clinical Principle Study for BBT-401, an Investigational Drug for Ulcerative Colitis
SEONGNAM, South Korea, June 13, 2021 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330) announced today the first patient dosing of BBT-401 at mid to high doses in its proof of clinical principle (PoCP) study to examine the drug's efficacy and safety in active ulcerative colitis (NCT04596293). Th...
Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for BBT-401 in Patients with Ulcerative Colitis; Rectal Delivery of Drug to Target Site
* The new proof of mechanism trial in ulcerative colitis had its first patient dosed inNew Zealand * In parallel with the oral-administered, proof of clinical principle study, the new proof of mechanism study will examine the efficacy of BBT-401 when delivered directly to the target organ via...
Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S
SEONGNAM, South Korea, April 6, 2021 /PRNewswire/ -- Bridge Biotherapeutics Inc.(288330 KQ), a clinical-stage biotech company headquartered in Seongnam, Republic of Korea, announced that the company has initiated the Phase 1/2 clinical trial assessing safety, tolerability, and anti-tumor activity...
Termination of Bridge Biotherapeutics's Collaboration and License Agreement with Boehringer Ingelheim
SEONGNAM, South Korea, Nov. 9, 2020 /PRNewswire/ -- On November 9, 2020, Bridge Biotherapeutics (288330 KQ) reported to the Korea Stock Exchange that the Company and Boehringer Ingelheim have mutually agreed on the termination of the Collaboration and License Agreement entered into inJuly 2019 to...
Bridge Biotherapeutics becomes BaseLaunch's first Asia Pacific partner
SEONGNAM, South Korea and BASEL, Switzerland, July 14, 2020 /PRNewswire/ -- Bridge Biotherapeutics Inc.(KOSDAQ: 288330), a clinical stage biotech company headquartered in Seongnam, Republic of Korea and BaseLaunch, theBasel Area -based biotech venture accelerator and incubator, today announces tha...
Bridge Biotherapeutics Announces the IND Clearance of BBT-176, an EGFR TKI for NSCLC, in South Korea
* Following the US FDA's IND clearance, South Korea's MFDS cleared the IND application of BBT-176, submitted inDecember 2019 * BBT-176 will be the company's first drug candidate to launch clinical studies inSouth Korea * In the second half of this year, the company is expected to initiate a ...
Bridge Biotherapeutics Discloses Interim Results from the First Cohort of Phase 2a Study of BBT-401, an Experimental Drug for Ulcerative Colitis
* The Interim data showed that 3 out of 9 evaluable patients on BBT-401 responded with more than 30% reduction in Total Mayo Score or 25% reduction in Partial Mayo Score * Safety and tolerability profiles remain consistent with results from Phase I trial in healthy volunteers SEONGNAM, South ...
Bridge Biotherapeutics Announces China NMPA Clearance of IND for BBT-401, a Pellino-1 Inhibitor for UC
* China NMPA cleared the IND application of BBT-401 submitted on September 25, 2019 * The Phase I clinical study in China will be initiated in May 2020 SEONGNAM, South Korea, Dec. 26, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KOSDAQ: 288330), a clinical stage biotech company headquart...
